Research programme: norovirus and rotavirus vaccine - University of Tampere/UMN Pharma

Drug Profile

Research programme: norovirus and rotavirus vaccine - University of Tampere/UMN Pharma

Alternative Names: UMN-2002; UMN-2003

Latest Information Update: 10 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Tampere Vaccine Research Center
  • Developer UMN Pharma; University of Tampere Vaccine Research Center
  • Class Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Gastroenteritis; Norovirus infections; Rotavirus infections

Most Recent Events

  • 10 Oct 2016 norovirus and rotavirus vaccine are still in preclinical development in Rotavirus-infections, Gastroenteritis and Norovirus-infections (In children, Prevention) in Finland (Parenteral, Injection) (UMN Pharma pipeline, October 2016)
  • 10 Oct 2016 UMN Pharma plans a phase I/II trial for UMN 2003 for acute Gastroenteritis in Finland (UMN Pharma pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gastroenteritis(In children, Prevention) in Finland (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top